ΕΛ.Ι.Ε.Κ.

Δημοσιεύσεις 2012

VASCULAR ENDOTHELIAL GROWTH FACTOR POLYMORPHISMS AND CLINICAL OUTCOME IN COLORECTAL CANCER PATIENTS TREATED WITH IRINOTECAN-BASED CHEMOTHERAPY AND BEVACIZUMAB IN THE FIRST-LINE SETTING

A.K. Koutras, A. Antonacopoulou, A.G. Eleftheraki, A. Koumarianou, I. Varthalitis, F. Fostira, I. Sgouros, E. Briasoulis, E. Bournakis, D. Bafaloukos, I. Bombolaki, E. Galani, D. Pectasides, G. Foutzilas, H.P. Kalofonos

Pharmacogenomics J.2012 Dec;12(6):468-75. doi: 10.1038/tpj.2011.37.

TRIPLE-NEGATIVE PHENOTYPE IS OF ADVERSE PROGNOSTIC VALUE IN PATIENTS TREATED WITH DOSE-DENSE SEQUENTIAL ADJUVANT CHEMOTHERAPY: A TRANSLATIONAL RESEARCH ANALYSIS IN THE CONTEXT OF A HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG) RANDOMIZED PHASE III TRIAL

P. Skarlos, C. Christodoulou, K.T Kalogeras, A.G Eleftheraki, M. Bobos, A. Batistatou, C. Valavanis, O. Tzaida, E. Timotheadou, R. Kronenwett, R.M Wirtz, I. Kostopoulos, D. Televantou, E. Koutselini, I. Papaspirou, C.A Papadimitriou, D. Pectasides, H. Gogas, G. Aravantinos, N. Pavlidis, P. Arapantoni, D.V Skarlos, G. Fountzilas

Cancer Chemother Pharmacol. 2012 Feb;69(2):533-46. doi: 10.1007/s00280-011-1730-9.

EXPRESSION OF ANGIOGENIC MARKERS IN THE PERIPHERAL BLOOD OF DOCETAXEL-TREATED ADVANCED BREAST CANCER PATIENTS. A HELLENIC ONCOLOGY GROUP (HECOG) STUDY

D. Pectasides, G. Papaxoinis, V. Kotoula, H. Fountzilas, I. Korantzis, A. Koutras, A.M. Dimopoulos, P. Papakostas, G. Aravantinos, I. Varthalitis, P. Kosmidis, D. Skarlos, E. Bournakis, D. Bafaloukos, H.P. Kalofonos, K.T. Kalogeras, G.Fountzilas

Oncol Rep. 2012 Jan;27(1):216-24. doi: 10.3892/or.2011.1504.

VOLUMETRIC AND MGMT PARAMETERS IN GLIOBLASTOMA PATIENTS: SURVIVAL ANALYSIS

G. Iliadis, V. Kotoula, A.Chatzisotiriou, D. Televantou, A.G. Eleftheraki, S. Lambaki, D. Misailidou, P. Selviaridis, G. Fountzilas

BMC Cancer 2012 Jan 3;12:

HER2 AND TOP2A IN HIGH-RISK EARLY BREAST CANCER PATIENTS TREATED WITH ADJUVANT EPIRUBICIN-BASED DOSE-DENSE SEQUENTIAL CHEMOTHERAPY

G. Fountzilas, Ch. Valavanis, V. Kotoula, A.G. Eleftheraki, K.T. Kalogeras, O. Tzaida, A. Batistatou, R. Kronenwett, R.M. Wirtz, M. Bobos, E. Timotheadou, N. Soupos, G. Pentheroudakis, H. Gogas, D. Vlachodimitropoulos, G. Polychronidou, G. Aravantinos, A. Koutras, Ch. Christodoulou, D. Pectasides and P.Arapantoni

J Trans Med. 2012 Jan 12;10:10. doi: 10.1186/1479-5876-10-10

IDENTIFICATION AND VALIDATION OF GENE EXPRESSION MODELS THAT PREDICT CLINICAL OUTCOME IN PATIENTS WITH EARLY-STAGE LARYNGEAL CANCER

E. Fountzilas, K. Markou, K. Vlachtsis, A. Nikolaou, P. Arapantoni-Dadioti, E. Ntoula, G. Tassopoulos, M. Bobos, P. Konstatninopoulos, G. Fountzilas & D. Spentzos

Ann Oncol.2012 Aug;23(8):2146-53. doi: 10.1093/annonc/mdr576

PROGNOSTIC UTILITY OF ANGIOGENESIS AND HYPOXIA EFFECTORS IN PATIENTS WITH OPERABLE SQUAMOUS CELL CANCER OF THE LARYNX

G. Pentheroudakis, I. Nicolaou, V. Kotoula, H. Fountzilas, K. Markou, A.G. Eleftheraki, A. Fragkoulidi, I. Karasmanis, A. Tsigka, N. Angouridakis, K. Vlachtsis, A. Nikolaou, N. Pavlidis, G. Fountzilas

Oral Oncol. 2012 Aug;48(8):709-16. doi: 10.1016/j.oraloncology.2012.02.002 (Epub 2012 Feb 25)

DIFFERENTIAL RESPONSE OF IMMUNOHISTOCHEMICALLY DEFINED BREAST CANCER SUBTYPES TO DOSE-DENSE SEQUENTIAL ADJUVANT CHEMOTHERAPY

G. Fountzilas, U. Dafni, M. Bobos, A. Batistatou, V. Kotoula, H. Trihia, V. Malamou-Mitsi, S. Miliaras, S. Chrisafi, S. Papadopoulos, M. Sotiropoulou, Th. Fillipidis, H. Gogas, T. Koletsa, D. Bafaloukos, D. Televantou, K.T. Kalogeras, D. Pectasides, D.V. Skarlos, A. Koutras, M.A. Dimopoulos

PloS One. 2012;7(6):e37946. doi: 10.1371/journal.pone.0037946

IMPROVED OUTCOME OF HIGH-RISK EARLY HER2-POSITIVE BREAST CANCER WITH HIGH CXCL13/CXCR5 MRNA EXPRESSION

E. Razis, K.T. Kalogeras, V. Kotoula, A.G. Eleftheraki, N. Nikitas, R. Kronenwett, E. Timotheadou, Ch. Christodoulou, D. Pectasides, H. Gogas, R.M. Wirtz, Th.Makatsoris, Di. Bafaloukos, G. Aravantinos, D. Televantou, N. Pavlidis, G. Fountzilas

Clin Breast Cancer. 2012 Jun;12(3):183-93. doi: 10.1016/j.clbc.2012.03.006

INDUCTION CHEMOTHERAPY FOLLOWED BY CONCOMITANT RADIOTHERAPY AND WEEKLY CISPLATIN VERSUS THE SAME CONCOMITANT CHEMORADIOTHERAPY IN PATIENTS WITH NASOPHARYNGEAL CARCINOMA: A RANDOMIZED PHASE II STUDY CONDUCTED BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG) WITH BIOMARKER EVALUATION

G. Fountzilas, E. Ciuleanu, M. Bobos, A. Kalogera-Fountzila, A.G. Eleftheraki, G. Karayannopoulou, T. Zaramboukas, A. Nikolaou, K. Markou, L. Resiga, D. Dionysopoulos, E. Samantas, H. Athanassiou, D. Misailidou, D. Skarlos, T. Ciuleanu

Ann Oncol. 2012 Feb;23(2):427-35. doi: 10.1093/annonc/mdr116

TOPOISOMERASE II alpha GENE AMPLIFICATION IS A FAVORABLE PROGNOSTIC FACTOR IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER TREATED WITH TRASTUZUMAB

G. Fountzilas, Ch. Christodoulou, M. Bobos, V. Kotoula, A.G. Eleftheraki, I. Xanthakis, A. Batistatou, G. Pentheroudakis, N. Xiros, I. Papaspirou, A. Koumarianou, P. Papakostas, D. Bafaloukos, D.V. Skarlos, K.T. Kalogeras

J Transl Med. 2012 Oct 23;10:212. doi: 10.1186/1479-5876-10-212

PREVALENCE OF BRCA1 MUTATIONS AMONG 403 WOMEN WITH TRIPLE-NEGATIVE BREAST CANCER: IMPLICATIONS FOR GENETIC SCREENING SELECTION CRITERIA: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY

F. Fostira, M. Tsitlaidou, C. Papadimitriou, M. Pertesi, E. Timotheadou, A.V. Stavropoulou, S. Glentis, E. Bournakis, M. Bobos, D. Pectasides, P. Papakostas, G. Pentheroudakis, H. Gogas, P. Skarlos, E. Samantas, D. Bafaloukos, P.A. Kosmidis, A. Koutras, D. Yannoukakos, I. Konstantopoulou, G. Fountzilas

Breast Cancer Res. Treat. 2012 Jul;134(1):353-62. doi: 10.1007/s10549-012-2021-9

V. Kotoula, D. Krikelis, V. Karavasilis, T. Koletsa, A.G. Eleftheraki, D. Televantou, Ch. Christodoulou, S. Dimoudis, I. Korantzis, D. Pectasides, K.N. Syrigos, P. A Kosmidis, G. Fountzilas

BMC Cancer. 2012 Aug 6;12:342. doi: 10.1186/1471-2407-12-342

I. Korantzis, K.T Kalogeras, G. Papaxoinis, V. Kotoula, A. Koutras, N. Soupos, P. Papakostas, D. Dionysopoulos, E. Samantas, Ch. Christodoulou, H. Linardou, D. Pectasides, G. Fountzilas

Anticancer Res. 2012 Oct;32(10):4569-80